[Antithrombotic activity of RU-891 antiaggregant agent].

Antithrombotic action of the novel benzimidazole derivative RU-891 exhibiting antiaggregant activity both in vitro and in vivo has been investigated in comparison to acetylsalicylic acid using the method of thrombosis induced by 50% ferrous chloride solution in rats. RU-891 compound showed dose-dependent antithrombotic activity exceeding that of the reference drug. Taking into account pathogenesis of this experimental thrombosis, it can be suggested that the antithrombotic action ofRU-891 is connected to its antiaggregant activity.